Insights into immune responses in oral cancer through proteomic analysis of saliva and salivary extracellular vesicles

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Winck, Flavia V ^a   Ribeiro, Ana Carolina Prado ^b   Domingues, Romênia Ramos ^a   Ling, Liu Yi ^c   Riaño Pachón, Diego Mauricio ^c   Rivera, César ^a,e   Brandão, Thaís Bianca ^b   Gouvea, Adriele Ferreira ^b   Santos Silva, Alan Roger ^d   Coletta, Ricardo D ^d   Leme, Adriana F Paes ^a  

^a BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e UNIVERSIDAD DE TALCA   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME; TUMOR MARKER;

ADULT; AGED; EXOSOME; FEMALE; HUMAN; IMMUNOLOGY; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PROCEDURES; PROGNOSIS; PROTEOMICS; SALIVA; TANDEM MASS SPECTROMETRY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHROMATOGRAPHY, LIQUID; EXTRACELLULAR VESICLES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; PROTEOME; PROTEOMICS; SALIVA; TANDEM MASS SPECTROMETRY;

EID: 84946594100     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16305     Document Type: Article

References (56)

1. van der Waal, I. Are we able to reduce the mortality and morbidity of oral cancer; some considerations. Med Oral Patol Oral Cir Bucal 18, e33-37, doi: 10.4317/medoral.18486 (2013).
2. Hauw, J. J., Boutry, J. M., Guillermin, A. M., Barbe, M. P. & Boissonnet, H. A new promotor of nerve growth: naftidrofuryl. C R Acad Sci III 302, 543-548 (1986).
3. Lippman, S. M., Sudbo, J. & Hong, W. K. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23, 346-356, doi: 10.1200/JCO.2005.09.128 (2005).
4. Sudbo, J. Novel management of oral cancer: a paradigm of predictive oncology. Clin Med Res 2, 233-242 (2004).
5. Carvalho, A. L., Nishimoto, I. N., Califano, J. A. & Kowalski, L. P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114, 806-816, doi: 10.1002/ijc.20740 (2005).
6. Jerjes, W. et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol 2, 9, doi: 10.1186/1758-3284-2-9 (2010).
7. da Silva, S. D. et al. Advances and applications of oral cancer basic research. Oral Oncol 47, 783-791, doi: 10.1016/j. oraloncology.2011.07.004 (2011).
8. Yan, W. et al. Systematic comparison of the human saliva and plasma proteomes. Proteomics Clin Appl 3, 116-134, doi: 10.1002/prca.200800140 (2009).
9. Cheng, L., Sharples, R. A., Scicluna, B. J. & Hill, A. F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 3, doi: 10.3402/jev.v3.23743 (2014).
10. Markopoulos, A. K., Michailidou, E. Z. & Tzimagiorgis, G. Salivary markers for oral cancer detection. Open Dent J 4, 172-178, doi: 10.2174/1874210601004010172 (2010).
11. D'Souza-Schorey, C. & Clancy, J. W. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 26, 1287-1299, doi: 10.1101/gad.192351.112 (2012).
12. Choi, D. S., Kim, D. K., Kim, Y. K. & Gho, Y. S. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 13, 1554-1571, doi: 10.1002/pmic.201200329 (2013).
13. Tang, H., Wu, Z., Zhang, J. & Su, B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep 7, 761-766, doi: 10.3892/mmr.2012.1254 (2013).
14. Shpitzer, T. et al. Salivary analysis of oral cancer biomarkers. British journal of cancer 101, 1194-1198, doi: 10.1038/sj.bjc.6605290 (2009).
15. Jessie, K. et al. Aberrant proteins in the saliva of patients with oral squamous cell carcinoma. Electrophoresis 34, 2495-2502, doi: 10.1002/elps.201300107 (2013).
16. Sivadasan, P. et al. Human salivary proteome-a resource of potential biomarkers for oral cancer. Journal of proteomics, doi: 10.1016/j.jprot.2015.05.039 (2015).
17. Arellano-Garcia, M. E. et al. Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis 14, 705-712, doi: 10.1111/j.1601-0825.2008.01488.x. (2008).
18. Leung, E. L. et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5, e14062, doi: 10.1371/journal.pone.0014062 (2010).
19. Yanagawa, H. et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 71, 1095-1098 (1995).
20. Zhang, Y. et al. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3KAkt-Erk pathway. J Cell Physiol 227, 35-43, doi: 10.1002/jcp.22722 (2012).
21. Lamb, J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7, 54-60, doi: 10.1038/nrc2044 (2007).
22. Ceciliani, F., Giordano, A. & Spagnolo, V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett 9, 211-223 (2002).
23. Dowling, P. et al. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. International journal of cancer. Journal international du cancer 131, 911-923, doi: 10.1002/ijc.26462 (2012).
24. Denny, P. et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. Journal of Proteome Research 7, 1994-2006, doi: 10.1021/pr700764j (2008).
25. Lengyel, E. Ovarian cancer development and metastasis. Am J Pathol 177, 1053-1064, doi: 10.2353/ajpath.2010.100105 (2010).
26. Cho, M. S. et al. Autocrine effects of tumor-derived complement. Cell Rep 6, 1085-1095, doi: 10.1016/j.celrep.2014.02.014 (2014).
27. Lim, J. et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J 27, 822-831, doi: 10.1096/fj.12-220582 (2013).
28. Kindt, N. et al. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol 139, 727-737, doi: 10.1007/s00432-013-1375-7 (2013).
29. Kindt, N. et al. Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells. Int J Oncol 43, 185-193, doi: 10.3892/ijo.2013.1944 (2013).
30. Carli, C., Metz, C. N., Al-Abed, Y., Naccache, P. H. & Akoum, A. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: involvement of novel kinase signaling pathways. Endocrinology 150, 3128-3137, doi: 10.1210/en.2008-1088 (2009).
31. Calandra, T. & Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3, 791-800, doi: 10.1038/nri1200 (2003).
32. Rakoff-Nahoum, S. Why cancer and inflammation? Yale J Biol Med 79, 123-130 (2006).
33. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18, 883-891, doi: 10.1038/nm.2753 (2012).
34. Shao, H. et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18, 1835-1840, doi: 10.1038/nm.2994 (2012).
35. Rokavec, M. et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 124, 1853-1867, doi: 10.1172/JCI73531 (2014).
36. Li, J., Ji, Z., Qiao, C., Qi, Y. & Shi, W. Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion. J Invest Surg, doi: 10.3109/08941939.2012.728682 (2013).
37. Micocci, K. C. et al. ADAM9 silencing inhibits breast tumor cell invasion in vitro. Biochimie 95, 1371-1378, doi: 10.1016/j. biochi.2013.03.001 (2013).
38. Salama, I., Malone, P. S., Mihaimeed, F. & Jones, J. L. A review of the S100 proteins in cancer. Eur J Surg Oncol 34, 357-364 (2008).
39. Choi, D. K. et al. Clinicopathological roles of S100A8 and S100A9 in cutaneous squamous cell carcinoma in vivo and in vitro. Arch Dermatol Res, doi: 10.1007/s00403-014-1453-y (2014).
40. Namura, T. et al. [Possible mechanism for regulation of inflammatory responses with the S100A8/A9 protein]. Rinsho Byori 58, 651-657 (2010).
41. Nigro, P., Pompilio, G. & Capogrossi, M. C. Cyclophilin A: a key player for human disease. Cell Death Dis 4, e888, doi: 10.1038/cddis.2013.410 (2013).
42. Pfeffer, S. R., Dirac-Svejstrup, A. B. & Soldati, T. Rab GDP dissociation inhibitor: putting rab GTPases in the right place. J Biol Chem 270, 17057-17059 (1995).
43. Casalou, C. et al. Arl13b and the non-muscle myosin heavy chain IIA are required for circular dorsal ruffle formation and cell migration. J Cell Sci, doi: 10.1242/jcs.143446 (2014).
44. Morin, N. A. et al. Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration. J Exp Med 205, 195-205, doi: 10.1084/jem.20071543 (2008).
45. Jacobelli, J., Estin Matthews, M., Chen, S. & Krummel, M. F. Activated T cell trans-endothelial migration relies on myosin-IIA contractility for squeezing the cell nucleus through endothelial cell barriers. PLoS One 8, e75151, doi: 10.1371/journal. pone.0075151 (2013).
46. Derycke, L. et al. The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol 55, 835-840, doi: 10.1387/ijdb.113336ld (2011).
47. Xiao, H. & Wong, D. T. Proteomic analysis of microvesicles in human saliva by gel electrophoresis with liquid chromatographymass spectrometry. Anal Chim Acta 723, 61-67, doi: 10.1016/j.aca.2012.02.018 (2012).
48. Gallo, A., Tandon, M., Alevizos, I. & Illei, G. G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 7, e30679, doi: 10.1371/journal.pone.0030679 (2012).
49. Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75, 663-670 (2003).
50. Villen, J. & Gygi, S. P. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nat Protoc 3, 1630-1638, doi: 10.1038/nprot.2008.150 (2008).
51. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26, 1367-1372, doi: 10.1038/nbt.1511 (2008).
52. Luber, C. A. et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 32, 279-289, doi: 10.1016/j.immuni.2010.01.013 (2010).
53. Storey, J. D., Taylor, J. E. & Siegmund, D. Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach. Journal of the Royal Statistical Society B 66, 187-205 (2004).
54. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431-432, doi: 10.1093/bioinformatics/btq675 (2011).
55. Goel, M. K., Khanna, P. & Kishore, J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 1, 274-278, doi: 10.4103/0974-7788.76794 (2010).
56. de Souza, J. E. et al. S-score: a scoring system for the identification and prioritization of predicted cancer genes. PLoS One 9, e94147, doi: 10.1371/journal.pone.0094147 (2014).